Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alzinova AB (publ) (ALZ.ST)
SEK0.72
-0.05 (-6.49%)
SE STO Healthcare Biotechnology
Address
Pepparedsleden 1 431 83
Mölndal, SE
Mölndal, SE
CEO
Tord Labuda
Website
alzinova.com
IPO
2015-11-25
ISIN SE0007413455
Description
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK0.72
-0.05 (-6.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.97
Float Shares
63.91M
Free Float %
60.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.32% | +10.42% | -21.87% | -35.94% | -71.53% | -45.77% | -74.55% | -80.94% | -92.28% | -96.09% | -95.77% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.72
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.09
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+16.1% Q1'26: +12.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-21.1% Q1'26: -14.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+50.4% Q1'26: +20.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
14.90M
est: 4.0K (+372,350.9%)
|
30.0K
est: 4.67M (-99.4%)
|
—
est: 37.50M (-100.0%)
|
31.35M
30.28M – 32.43M
-16.4% YoY
|
11.00M
11.00M – 11.00M
-64.9% YoY
|
9.25M
9.25M – 9.25M
-15.9% YoY
|
| EBITDA |
-6.50M
est: -2.0K (-324,831.9%)
|
-20.32M
est: -993.3K (-1,945.5%)
|
-25.85M
est: -7.98M (-223.9%)
|
-6.67M
-6.90M – -6.44M
+16.4% YoY
|
-2.34M
-2.34M – -2.34M
+64.9% YoY
|
-1.97M
-1.97M – -1.97M
+15.9% YoY
|
| EBIT |
-6.50M
est: -3.4K (-188,539.7%)
|
-20.32M
est: -2.27M (-794.3%)
|
-25.85M
est: -18.26M (-41.6%)
|
-15.26M
-15.79M – -14.74M
+16.4% YoY
|
-5.36M
-5.36M – -5.36M
+64.9% YoY
|
-4.50M
-4.50M – -4.50M
+15.9% YoY
|
| Net Income |
-6.50M
est: -46.62M (+86.1%)
|
-20.55M
est: -25.62M (+19.8%)
|
-26.27M
est: -23.11M (-13.7%)
|
-32.15M
-32.15M – -32.15M
-39.1% YoY
|
-49.23M
-49.23M – -49.23M
-53.1% YoY
|
-49.23M
-49.23M – -49.23M
+0.0% YoY
|
| SGA |
17.23M
est: 654.6K (+2,532.7%)
|
20.41M
est: 763.55M (-97.3%)
|
25.85M
est: 6.14B (-99.6%)
|
5.13B
4.95B – 5.31B
-16.4% YoY
|
1.80B
1.80B – 1.80B
-64.9% YoY
|
1.51B
1.51B – 1.51B
-15.9% YoY
|
| EPS |
-0.37
est: -0.70 (+47.0%)
|
-0.31
est: -0.26 (-21.6%)
|
-0.26
est: -0.23 (-13.0%)
|
-0.32
-0.32 – -0.32
-39.1% YoY
|
-0.49
-0.49 – -0.49
-53.1% YoY
|
-0.49
-0.49 – -0.49
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
Shares Outstanding
106.33M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anders Sandberg | Chief Scientific Officer | — | — |
| Erik Kullgren | Chief Financial Officer | — | male |
| Sebastian Hansson | Business Development Director | — | male |
| Tord Labuda | Chief Executive Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALZ.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
